Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Arthritis Drug Demonstrates Substantial Hair Regrowth in 1,400 Alopecia Patients
3+ day, 10+ hour ago (426+ words) An arthritis drug of all things was recently found in a study to restore up to 100% of hair in patients with severe alopecia. Around 2% of the world population live with alopecia areata, an autoimmune disorder where the human immune system…...
Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata
3+ day, 19+ hour ago (323+ words) The Clinical Trial Vanguard Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata Nektar Therapeutics went quiet on September 8, 2026, and will stay that way until it releases the 24-week off-treatment follow-up data from its Phase 2b REZOLVE-AA study of…...
QTTB: Phase II results support phase III advancement for a safe, effective alopecia areata therapy — TradingView News
4+ day, 4+ hour ago (75+ words) QTTB: Phase II results support phase III advancement for a safe, effective alopecia areata therapy TradingView QTTB: Phase II results support phase III advancement for a safe, effective alopecia areata therapy Positive phase II data for bempikibart in alopecia areata…...
Arthritis medication has been shown to be effective against alopecia, according to a study
5+ day, 11+ hour ago (331+ words) Upadacitinib, an anti-inflammatory drug used to treat arthritis, has been tested as a potential treatment for alopecia areata. An international team of researchers reported the results of two Phase III clinical trials in in a magazine JAMA Dermatology. A total…...
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
1+ week, 3+ day ago (378+ words) HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells Patent allowance received for use of HCW9302 as treatment for alopecia areata Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata…...
Forget GLP-1 stocks, baldness drugs are Wall Street???s next goldmine
2+ week, 10+ hour ago (603+ words) Drugmakers found a promising cure for the obesity epidemic and their stocks were rewarded for it. Now, investors are salivating over a new crop of companies tackling a more purely aesthetic problem: baldness. “People will fly all the way to…...
Upadacitinib Restored Substantial Scalp Hair in Severe Alopecia Areata, but Long-Term Safety and Durability Remain Unclear
2+ week, 20+ hour ago (1449+ words) Two Phase 3 trials involving 1,399 adults and adolescents found substantial scalp, eyebrow, and eyelash regrowth with upadacitinib after 24 weeks. The results are promising, but long-term safety, durability, and FDA approval for alopecia areata remain unresolved. Two randomized Phase 3 trials found that…...
Can We Add Upadacitinib to the Alopecia Areata Arsenal?
2+ week, 3+ day ago (689+ words) Docwire News Upadacitinib Shows Promising Efficacy for Alopecia Areata According to phase 3 data, upadacitinib may represent a potential treatment option for patients with severe alopecia areata. There is currently an unmet need for systemic therapies for alopecia areata—with only…...
Popular arthritis drug shown to restore hair in 55% of patients with severe alopecia in six months
3+ week, 1+ day ago (456+ words) WATCH NOW: Leslie Kenny reveals her top longevity foods The EU has approved the drug to treat alopecia after trials showed significant hair regrowth in over half of patients An arthritis medication manufactured by AbbVie has demonstrated striking results in…...
Further evidence for JAK inhibitors in severe AA
3+ week, 2+ day ago (548+ words) A pair of international phase 3 trials support the use of upadacitinib in the treatment of severe alopecia areata in adolescents and adults. Adolescent and adult patients with severe alopecia areata could soon have another oral treatment option available to them....